The next
generation...

Thermally Stable Highly immunogenic Needle Free Solid Dose Vaccines

In Action

Pause

aVaxziPen

technology

Solid Dose Vaccines

  • Smaller than a grain of rice
  • Delivers an accurate dose every time
  • No wasted vaccine

Solid Dose
Vaccine Delivery

  • Needle free
  • Delivered in microseconds
  • Fully dissolves in minutes
  • Gentle, fast & efficient

Scientific Data

Influenza vaccine in aVaxziPen’s solid dose formulation compared to a liquid control in preclinical studies:

Benefits

aVaxziPen offers a significantly lower carbon footprint than needle & syringe
Needle Free
Eliminates Vials No Mix & Shoot
Error Free Dosing
Eliminates Needle Stick Injury
Negates Risk of Needle Phobia
Eliminates Sharps Waste
Highly Immunogenic
Thermal Stability Reduces Waste
Easily Expanded Global Access
Reduced Distribution & Logistics Costs
Greatly Reduced Carbon Footprint
Cost Effective

The Team

aVaxziPen management team is made up of industry professionals with several decades of wide-ranging experience in the biotech industry.
Name

Robin Cohen

Chief Executive Officer & Executive Director
Name

Karen Stoddart

Chief Regulatory Officer & Executive Director
Name

Dr Carolyn Mercer

Chief Financial Officer & Executive Director
Name

Dr Keith Howard

Chief Scientific Officer
Name

Christopher Macgregor

Head of Research & Development
Name

Carol Lloyd

Executive Assistant & Company Secretary

Scientific Advisory Board

aVaxziPen Scientific Advisory Board comprises highly experienced and distinguished experts in vaccination and preventative health from leading academic research and international health organisation from across the US and Europe.
Name

Professor Jayne Hope

Name

Professor James Birchall

Name

Campbell Bunce PhD

Partnership

aVaxziPen works with a wide range of strategic partners.

To discuss the potential for your vaccine to become more thermally stable with higher immunogenicity, needle free and a greatly reduced carbon footprint…

Contact Us